LIEN
Price
$9.20
Change
+$0.10 (+1.10%)
Updated
Nov 4 closing price
Capitalization
209.95M
7 days until earnings call
Intraday BUY SELL Signals
SHPH
Price
$5.21
Change
+$0.06 (+1.17%)
Updated
Nov 4 closing price
Capitalization
24.82M
7 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

LIEN vs SHPH

LIEN vs SHPH Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
LIEN vs. SHPH commentary
Nov 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LIEN is a StrongBuy and SHPH is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for LIEN with price predictions
Nov 04, 2026

LIEN sees its Stochastic Oscillator climbs out of oversold territory

On October 27, 2026, the Stochastic Oscillator for LIEN moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 71 instances where the indicator left the oversold zone. In 46 of the 71 cases the stock moved higher in the following days. This puts the odds of a move higher at over 65%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where LIEN's RSI Oscillator exited the oversold zone, 15 of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 62%.

The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on LIEN as a result. In 55 of 113 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 49%.

The Moving Average Convergence Divergence (MACD) for LIEN just turned positive on October 27, 2026. Looking at past instances where LIEN's MACD turned positive, the stock continued to rise in 32 of 51 cases over the following month. The odds of a continued upward trend are 63%.

Following a +0.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where LIEN advanced for three days, in 111 of 200 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.

Bearish Trend Analysis

LIEN moved below its 50-day moving average on September 30, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for LIEN crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 60%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LIEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.

LIEN broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for LIEN entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. LIEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 65 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.694) is normal, around the industry mean (2.440). P/E Ratio (6.619) is within average values for comparable stocks, (-3.350). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.319). Dividend Yield (0.148) settles around the average of (0.267) among similar stocks. P/S Ratio (5.811) is also within normal values, averaging (15.694).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LIEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock worse than average.

A.I.Advisor
a Summary for SHPH with price predictions
Nov 04, 2026

Momentum Indicator for SHPH turns positive, indicating new upward trend

SHPH saw its Momentum Indicator move above the 0 level on October 30, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 65 similar instances where the indicator turned positive. In 57 of the 65 cases, the stock moved higher in the following days. The odds of a move higher are at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +5.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where SHPH advanced for three days, in 134 of 162 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

The Aroon Indicator entered an Uptrend today. In 34 of 45 cases where SHPH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 76%.

Bearish Trend Analysis

The 10-day RSI Indicator for SHPH moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 8 similar instances where the indicator moved out of overbought territory. In 8 of the 8 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Moving Average Convergence Divergence Histogram (MACD) for SHPH turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 34 similar instances when the indicator turned negative. In 31 of the 34 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SHPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

SHPH broke above its upper Bollinger Band on October 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.294) is normal, around the industry mean (7.659). P/E Ratio (0.539) is within average values for comparable stocks, (0.330). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (181.047).

The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. SHPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SHPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.

TECHNICAL ANALYSIS
Technical Analysis
LIENSHPH
RSI
ODDS (%)
Bullish Trend 2 days ago
63%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
65%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
49%
Bullish Trend 2 days ago
88%
MACD
ODDS (%)
Bullish Trend 2 days ago
63%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
54%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
61%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 8 days ago
56%
Bullish Trend 2 days ago
83%
Declines
ODDS (%)
Bearish Trend 3 days ago
57%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
61%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
45%
Bullish Trend 2 days ago
76%
COMPARISON
Comparison
Nov 05, 2026
Stock price -- (LIEN: $9.20 vs. SHPH: $5.21)
Brand notoriety: LIEN and SHPH are both not notable
LIEN represents the Investment Managers, while SHPH is part of the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: LIEN: 17% vs. SHPH: 19%
Market capitalization -- LIEN: $209.95M vs. SHPH: $24.82M
LIEN [@Investment Managers] is valued at $209.95M. SHPH’s [@Pharmaceuticals: Generic] market capitalization is $24.82M. The market cap for tickers in the [@Investment Managers] industry ranges from $1.59 to $189.62B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Investment Managers] industry is $8.76B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.39B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LIEN’s FA Score shows that 0 FA rating(s) are green while SHPH’s FA Score has 0 green FA rating(s).

  • LIEN’s FA Score: 0 green, 5 red.
  • SHPH’s FA Score: 0 green, 5 red.
According to our system of comparison, SHPH is a better buy in the long-term than LIEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LIEN’s TA Score shows that 5 TA indicator(s) are bullish while SHPH’s TA Score has 3 bullish TA indicator(s).

  • LIEN’s TA Score: 5 bullish, 5 bearish.
  • SHPH’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, LIEN is a better buy in the short-term than SHPH.

Price Growth

LIEN (@Investment Managers) experienced а +0.88% price change this week, while SHPH (@Pharmaceuticals: Generic) price change was -0.57% for the same time period.

The average weekly price growth across all stocks in the @Investment Managers industry was -3.43%. For the same industry, the average monthly price growth was -6.66%, and the average quarterly price growth was -6.20%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +4.74%. For the same industry, the average monthly price growth was +2.25%, and the average quarterly price growth was +25.89%.

Reported Earning Dates

LIEN is expected to report earnings on Nov 12, 2026.

SHPH is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Investment Managers (-3.43% weekly)

Investment Managers manage financial assets and other investments of clients. Management includes designing a short- or long-term strategy for buying/holding and selling of portfolio holdings. It can also include tax services and other aspects of financial planning as well. While it is perceived that the industry is faced with growing competition from robo-advisors/digital platforms and passive/ index-tracking funds, many investors still find value in actively managed in-person services that investment management companies often emphasize on. At the same time, many wealth managers are also incorporating digital initiatives/low cost options in addition to their in-person customized services. Their main sources of revenues are fees as a percentage of assets under management, in addition to a certain portion of clients’ gains from asset appreciation. BlackRock, Inc., Blackstone Group Inc and Brookfield Asset Management are some of the major investment management companies.

@Pharmaceuticals: Generic (+4.74% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
Interact to see
Advertisement

LIEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, LIEN has been loosely correlated with TXMD. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if LIEN jumps, then TXMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LIEN
1D Price
Change %
LIEN100%
+1.10%
TXMD - LIEN
36%
Loosely correlated
+2.25%
CGBD - LIEN
27%
Poorly correlated
+2.41%
KBDC - LIEN
24%
Poorly correlated
+0.78%
CSWC - LIEN
22%
Poorly correlated
+2.32%
MAAS - LIEN
21%
Poorly correlated
-7.93%
More

SHPH and

Correlation & Price change

A.I.dvisor tells us that SHPH and LFCR have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SHPH and LFCR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SHPH
1D Price
Change %
SHPH100%
+1.17%
LFCR - SHPH
31%
Poorly correlated
+0.31%
YCBD - SHPH
22%
Poorly correlated
-3.10%
LIEN - SHPH
21%
Poorly correlated
+1.10%
SXTC - SHPH
21%
Poorly correlated
+3.47%
RMTI - SHPH
20%
Poorly correlated
-0.49%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
DFE76.411.62
+2.16%
WisdomTree Europe SmallCap Dividend Fund (DFE)
FSEV26.730.36
+1.38%
Fidelity Enhanced Small Cap Value ETF (FSEV)
FLBR20.120.27
+1.36%
Franklin FTSE Brazil ETF (FLBR)
FEBM31.860.11
+0.35%
FT Vest US Equity Max Buffer ETF-February (FEBM)
AIA126.66-0.06
-0.05%
iShares Asia 50 ETF (AIA)